Education
About Us
Working with TipRanks
Follow Us
Enzon Pharmaceuticals (ENZN)
OTHER OTC:ENZN
ENZN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.06 - $0.24
Previous CloseN/A
Volume3.72K
Average Volume (3M)47.44K
Market Cap
$5.88M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)38.2
Beta0.59
Next EarningsN/A
EPS EstimateN/A
Last Dividend Ex-Date
Sep 30, 2019Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding74,214,600
10 Day Avg. Volume30,857
30 Day Avg. Volume47,437
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Enzon Pharmaceuticals News
ENZN FAQ
What was Enzon Pharmaceuticals’s price range in the past 12 months?
Enzon Pharmaceuticals lowest stock price was $0.06 and its highest was $0.23 in the past 12 months.
What is Enzon Pharmaceuticals’s market cap?
Enzon Pharmaceuticals’s market cap is $5.88M.
When is Enzon Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Enzon Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Enzon Pharmaceuticals overvalued?
According to Wall Street analysts Enzon Pharmaceuticals’s price is currently Overvalued.
Does Enzon Pharmaceuticals pay dividends?
Enzon Pharmaceuticals pays a Semiannually dividend of $0.12 which represents an annual dividend yield of N/A. See more information on Enzon Pharmaceuticals dividends here
What is Enzon Pharmaceuticals’s EPS estimate?
Enzon Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enzon Pharmaceuticals have?
Enzon Pharmaceuticals has 74,214,600 shares outstanding.
What happened to Enzon Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Enzon Pharmaceuticals?
Currently, no hedge funds are holding shares in ENZN
Company Description
Enzon Pharmaceuticals
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
Enzon Pharmaceuticals (ENZN) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
AIM ImmunoTech
―
Titan Pharmaceuticals
―
GT Biopharma
―
PharmaCyte Biotech
―
Processa Pharmaceuticals
―
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---